Name | Number of supported studies | Average coverage | |
---|---|---|---|
peripheral blood | 17 studies | 36% ± 10% | |
lung | 7 studies | 27% ± 6% | |
brain | 5 studies | 24% ± 4% | |
intestine | 5 studies | 21% ± 7% | |
kidney | 4 studies | 22% ± 4% | |
uterus | 4 studies | 22% ± 7% | |
liver | 4 studies | 32% ± 23% | |
lymph node | 4 studies | 26% ± 5% | |
pancreas | 3 studies | 38% ± 13% | |
bone marrow | 3 studies | 31% ± 12% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
brain | 100% | 4209.42 | 2642 / 2642 | 100% | 54.74 | 705 / 705 |
esophagus | 100% | 3358.49 | 1445 / 1445 | 100% | 30.09 | 183 / 183 |
intestine | 100% | 3471.79 | 966 / 966 | 100% | 37.11 | 527 / 527 |
kidney | 100% | 3531.35 | 89 / 89 | 100% | 34.35 | 901 / 901 |
liver | 100% | 2740.07 | 226 / 226 | 100% | 26.61 | 406 / 406 |
ovary | 100% | 3113.02 | 180 / 180 | 100% | 25.57 | 430 / 430 |
prostate | 100% | 3288.06 | 245 / 245 | 100% | 48.01 | 502 / 502 |
stomach | 100% | 2533.39 | 359 / 359 | 100% | 32.87 | 286 / 286 |
thymus | 100% | 3579.13 | 653 / 653 | 100% | 55.30 | 605 / 605 |
uterus | 100% | 3258.94 | 170 / 170 | 100% | 43.68 | 459 / 459 |
lung | 100% | 2828.84 | 578 / 578 | 100% | 35.40 | 1154 / 1155 |
bladder | 100% | 3549.10 | 21 / 21 | 100% | 36.85 | 503 / 504 |
skin | 100% | 3485.58 | 1809 / 1809 | 100% | 35.83 | 471 / 472 |
pancreas | 100% | 1865.07 | 327 / 328 | 100% | 34.76 | 178 / 178 |
breast | 100% | 3303.53 | 459 / 459 | 100% | 43.02 | 1114 / 1118 |
adrenal gland | 100% | 3090.38 | 258 / 258 | 100% | 41.07 | 229 / 230 |
adipose | 100% | 3237.58 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 3975.79 | 1335 / 1335 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 49.39 | 29 / 29 |
muscle | 100% | 3467.22 | 803 / 803 | 0% | 0 | 0 / 0 |
peripheral blood | 100% | 5660.08 | 929 / 929 | 0% | 0 | 0 / 0 |
spleen | 100% | 3389.32 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 42.45 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 29.39 | 1 / 1 |
heart | 99% | 2025.18 | 852 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 98% | 24.30 | 78 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0000398 | Biological process | mRNA splicing, via spliceosome |
GO_0007059 | Biological process | chromosome segregation |
GO_0060629 | Biological process | regulation of homologous chromosome segregation |
GO_0045292 | Biological process | mRNA cis splicing, via spliceosome |
GO_0000775 | Cellular component | chromosome, centromeric region |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005829 | Cellular component | cytosol |
GO_0005681 | Cellular component | spliceosomal complex |
GO_0005634 | Cellular component | nucleus |
GO_0030623 | Molecular function | U5 snRNA binding |
GO_0005515 | Molecular function | protein binding |
Gene name | C9orf78 |
Protein name | Hepatocellular carcinoma-associated antigen 59 Splicing factor C9orf78 (Hepatocellular carcinoma-associated antigen 59) |
Synonyms | HCA59 |
Description | FUNCTION: Plays a role in pre-mRNA splicing by promoting usage of the upstream 3'-splice site at alternative NAGNAG splice sites; these are sites featuring alternative acceptor motifs separated by only a few nucleotides . May also modulate exon inclusion events . Plays a role in spliceosomal remodeling by displacing WBP4 from SNRNP200 and may act to inhibit SNRNP200 helicase activity . Binds U5 snRNA . Required for proper chromosome segregation . Not required for splicing of shelterin components . . |
Accessions | ENST00000372447.7 Q6GVN4 Q9NZ63 |